These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31231083)

  • 1. Familial Hypercholesterolemia and Lipoprotein Apheresis.
    Makino H; Koezuka R; Tamanaha T; Ogura M; Matsuki K; Hosoda K; Harada-Shiba M
    J Atheroscler Thromb; 2019 Aug; 26(8):679-687. PubMed ID: 31231083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDL apheresis in Japan.
    Makino H; Tamanaha T; Harada-Shiba M
    Transfus Apher Sci; 2017 Oct; 56(5):677-681. PubMed ID: 28964708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Position of lipoprotein apheresis in present].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Vrablík M; Piťha J; Žák P; Sobotka L
    Vnitr Lek; 2015 Nov; 61(11):958-64. PubMed ID: 26652784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
    Santos RD; Stein EA; Hovingh GK; Blom DJ; Soran H; Watts GF; López JAG; Bray S; Kurtz CE; Hamer AW; Raal FJ
    J Am Coll Cardiol; 2020 Feb; 75(6):565-574. PubMed ID: 32057369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children.
    Page MM; Bell DA; Hooper AJ; Watts GF; Burnett JR
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):387-403. PubMed ID: 24840266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
    Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ;
    Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
    Moriarty PM; Parhofer KG; Babirak SP; deGoma E; Duell PB; Hohenstein B; Ramlow W; Simha V; Steinhagen-Thiessen E; Thompson PD; Vogt A; von Stritzky B; Du Y; Manvelian G
    J Clin Lipidol; 2016; 10(3):627-34. PubMed ID: 27206951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
    Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances.
    Stefanutti C; Thompson GR
    Curr Atheroscler Rep; 2015 Jan; 17(1):465. PubMed ID: 25410046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
    Lappegård KT; Kjellmo CA; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Karlsson H; Hovland A
    Transfus Apher Sci; 2018 Feb; 57(1):91-96. PubMed ID: 29398508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
    Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
    Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion.
    Ishii T; Ogura M; Nakamori H; Hori M; Harada-Shiba M; Tamura K; Oyama K
    CEN Case Rep; 2021 Nov; 10(4):592-597. PubMed ID: 34100221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.
    Tavori H; Giunzioni I; Linton MF; Fazio S
    Circ Res; 2013 Dec; 113(12):1290-5. PubMed ID: 24122718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.